Literature DB >> 17555844

Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update.

Jean-Marc Muller1, Colin Debaigt, Stéphanie Goursaud, Alicia Montoni, Nicolas Pineau, Annie-Claire Meunier, Thierry Janet.   

Abstract

The 28-amino-acid neuropeptide VIP and related peptides PACAP and PHI/PHM modulate virtually all of the vital functions in the body. These peptides are also commonly recognized as major regulators of cell growth and differentiation. Through their trophic and cytoprotective functions, they appear to play major roles in embryonic development, neurogenesis and the progression of a number of cancer types. These peptides bind to three well-characterized subtypes of G-protein coupled receptors: VPAC1 and VPAC2 share a common high affinity in the nanomolar range for VIP and PACAP; a third receptor type, PAC1, has been characterized for its high affinity for PACAP but its low affinity for VIP. Complex effects and pharmacological behaviors of these peptides suggest that multiple subtypes of binding sites may cooperate to mediate their function in target cells and tissues. In this complex response, some of these binding sites correspond to the definition of the conventional receptors cited above, while others display unexpected pharmacological and functional properties. Here we present potential clues that may lead investigators to further characterize the molecular nature and functions of these atypical binding species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555844     DOI: 10.1016/j.peptides.2007.04.006

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

Review 1.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 2.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

3.  Pituitary adenylate cyclase-activating polypeptide deficiency enhances oxazolone-induced allergic contact dermatitis in mice.

Authors:  Agnes Kemény; Dóra Reglodi; Renáta Cseharovszky; Hitoshi Hashimoto; Akemichi Baba; János Szolcsányi; Erika Pintér; Zsuzsanna Helyes
Journal:  J Mol Neurosci       Date:  2010-04-23       Impact factor: 3.444

Review 4.  VIP-induced neuroprotection of the developing brain.

Authors:  Sandrine Passemard; Paulina Sokolowska; Leslie Schwendimann; Pierre Gressens
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

5.  Investigation of the possible functions of PACAP in human trophoblast cells.

Authors:  G Horvath; D Reglodi; R Brubel; M Halasz; A Barakonyi; A Tamas; E Fabian; B Opper; G Toth; M Cohen; L Szereday
Journal:  J Mol Neurosci       Date:  2014-05-30       Impact factor: 3.444

6.  Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells.

Authors:  D Reglodi; R Borzsei; T Bagoly; A Boronkai; B Racz; A Tamas; P Kiss; G Horvath; R Brubel; J Nemeth; G Toth; Z Helyes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

7.  Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor.

Authors:  Chandramohan Natarajan; Aaron N Hata; Heidi E Hamm; Roy Zent; Richard M Breyer
Journal:  Mol Pharmacol       Date:  2012-10-18       Impact factor: 4.436

8.  Investigation of PACAP Fragments and Related Peptides in Chronic Retinal Hypoperfusion.

Authors:  Dora Werling; Dora Reglodi; Peter Kiss; Gabor Toth; Krisztina Szabadfi; Andrea Tamas; Zsolt Biro; Tamas Atlasz
Journal:  J Ophthalmol       Date:  2014-05-12       Impact factor: 1.909

9.  Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library.

Authors:  Bo Tang; Zhexu Li; Dingde Huang; Lei Zheng; Qianwei Li
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.